The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Resetting Immune Tolerance to Prevent RA

Resetting Immune Tolerance to Prevent RA

November 24, 2020 • By Mary Beth Nierengarten

  • Tweet
  • Email
Print-Friendly Version / Save PDF

ACR CONVERGENCE 2020—Likening the development of rheumatoid arthritis (RA) to water under the surface of an iceberg, in which what lies beneath is hidden from view, Ronald van Vollenhoven, MD, PhD, chair of the Department of Rheumatology and Clinical Immunology at the Amsterdam University Medical Centers of the University of Amsterdam, The Netherlands, provided an apt visual for a discussion on the etiology of RA and potential treatments to slow, stop or reverse the pathogenesis of preclinical RA before it manifests itself in its more debilitating, active disease form. Presented during the session Resetting Immune Tolerance for the Prevention of RA, Dr. van Vollenhoven joined two other experts to discuss the current evidence on potential pathogenic mechanisms underlying preclinical RA autoimmunity and subsequent active disease.

You Might Also Like
  • Resetting Immune Tolerance for the Prevention of RA
  • 2015 ACR/ARHP Annual Meeting: Research Provides Insights into Immune Regulation and Tolerance
  • Check It Out: Understanding Immune-Related Adverse Events from Immune Checkpoint Inhibitors
Also By This Author
  • Antibodies Against Oxidized Phospholipids Protect Against Osteoporosis

Dr. van Vollenhoven

“There is a great movement in trying to prevent RA by targeted interventions in the preclinical stage,” said Dr. van Vollenhoven, who also is the director of the Amsterdam Rheumatology Center.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

B Cell Depletion: Targeted Therapy?
Dr. van Vollenhoven reviewed research over the past decades that has established the role of anti-citrullinated peptide antibodies (ACPAs) and B cells in the development of preclinical RA autoimmunity. This research, he said, has provided a sound rationale for targeting B cells in the preclinical phase.

He then reviewed clinical results of the PRAIRI trial by Gerlag et al. that looked at whether B cell-directed therapy (or B cell depletion) using a single infusion of 1,000 mg rituximab could prevent RA in at-risk individuals.1 The biologic was not found to prevent RA in the high-risk cohort, but it did delay the onset of disease. Dr. van Vollenhoven suggested the results warrant further inquiry as to understand better why the therapy was not preventive, such as was the treatment not introduced early enough or was the single dose used not sufficiently strong enough?

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. van Vollenhoven underscored the importance going forward to improve prediction of which patients are at highest risk of developing RA to justify a treatment trial with bigger results. “The key challenges are identifying the patient who is at high risk and selecting optimal treatment,” he said.

Dr. Holers

Potential Pathogenic Mechanisms of Preclinical RA
V. Michael Holers, MD, Scoville Professor and head of the Division of Rheumatology at the University of Colorado School of Medicine, Denver, discussed ongoing work through the Studies of the Etiology of Rheumatoid Arthritis (SERA) program at the University of Colorado, examining the factors driving the initiation and development of seropositive RA. He highlighted evidence from multiple independent studies supporting a mucosal site of origin of preclinical RA autoimmunity in at-risk people—sites include the periodontium, intestine, cervicovagina, peripheral blood and lungs.2

Pages: 1 2 3 | Single Page

Filed Under: ACR Convergence, Conditions, Rheumatoid Arthritis Tagged With: ACR Convergence 2020, ACR Convergence 2020 – RA

You Might Also Like:
  • Resetting Immune Tolerance for the Prevention of RA
  • 2015 ACR/ARHP Annual Meeting: Research Provides Insights into Immune Regulation and Tolerance
  • Check It Out: Understanding Immune-Related Adverse Events from Immune Checkpoint Inhibitors
  • Research Offers Hope of New Therapies to Prevent Bone Loss and Destruction

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)